TABLE 3.
Characteristics of the studies included in the present meta-analysis.
| Study | year | Cancer | No. | Detection method | Survival Outcome |
Follow-up time (month) | NOS score |
|---|---|---|---|---|---|---|---|
| Barbagallo | 2019 | GBM | 31 | RT-qPCR | OS, PFS | ≥40 | 6 |
| Cai | 2019 | GC | 60 | RT-qPCR | OS, DFS, TNM | ≥40 | 7 |
| Liu | 2019 | MM | 105 | RT-qPCR | OS, PFS | ≥40 | 6 |
| Lu | 2020 | ICC | 92 | RT-qPCR | OS, TNM | ≥60 | 8 |
| Miao | 2020 | CRC | 45 | RT-qPCR | OS | ≥100 | 8 |
| Tong | 2020 | NSCLC | 460 | RT-qPCR | OS, DFS, TNM | ≥96 | 8 |
| Yu | 2018 | HCC | 40 | RT-qPCR | OS, RFS | ≥60 | 8 |
Abbreviations: GC: gastric cancer; GBM: glioblastoma; HCC: hepatocellular carcinoma; NSCLC: non-small -cell lung cancer; ICC: intrahepatic cholangiocarcinoma; MM: multiple myeloma; CRC: colorectal cancer.